FDA Approves First mRNA Flu Vaccine For Older Adults

The U.S. Food and Drug Administration has granted approval for mFLUSIVA, the first mRNA-based seasonal influenza vaccine. Developed by Moderna, the vaccine is specifically indicated for individuals aged 50 and older. It is currently slated for release during the 2026-2027 respiratory illness season.

This approval marks a significant development in vaccine technology, transitioning mRNA platforms—previously utilized for COVID-19—to seasonal flu prevention. By targeting the older adult demographic, the vaccine aims to address specific health risks associated with influenza in this age group as part of future immunization efforts.